Abiraterone Dosing Optimized with Genetic Factor

Introducing... Advanced Oncology! The latest addition to our high-impact collaborative journals - Advanced #Oncology accelerates breakthrough #cancerresearch with clarity, speed and purpose. It covers basic, translational and clinical oncology. We want to connect cancer researchers and oncologists worldwide who are driving cancer science forward. Advanced Oncology is where cancer biology meets bold innovation — without limits. 🚀 Edited by Dr. Ada Hang-Heng Wong. Come and explore what we're building: https://ow.ly/rfaa50YtgrX

Advanced Oncology is dedicated to advancing cancer research and clinical oncology in action by building partnership among academia, industry, and health practitioners. Please stay tuned for the coming of our industry-motivated multi-journal virtual issue.

A single breakthrough can redefine medicine, and Dr. Tony Hunter’s did exactly that. Dr. Tony Hunter’s pioneering discovery of tyrosine kinases and protein-tyrosine phosphorylation transformed our understanding of cancer and paved the way for more than 80 cancer therapies. In recognition of his contributions to science, he received the 2025 Dr. Paul Janssen Award for Biomedical Research. We were honored to welcome him to our site in Beerse, Belgium where science and collaboration continue to drive innovation in oncology and beyond. Read more: https://lnkd.in/eP2WERrk #Science #Oncology #DrPaulJanssenAward

📺 Andrew Armstrong of Duke Cancer Institute discusses new guidelines from Prostate Cancer Working Group 4, including the main drivers that necessitated the update, and how the new recommendations incorporate emerging biomarkers and data: https://buff.ly/t0DEzSM 🔬 Dr. Armstrong also elaborates on new imaging-specific rPFS criteria and updated intervals for imaging, and what he believes are the most critical areas that need a coordinated effort to support the next generation of #prostatecancer trials.

#Cholangiocarcinoma Theme Review #LegacyCOntent: Cholangiocarcinoma Targeted Therapies: Mechanisms of Action and Resistance. Authors from Mass General Cancer Center, Harvard Medical School, University of Glasgow, Cholangiocarcinoma Foundation and The University of Manchester. Full text: https://lnkd.in/exyM2cQV

Don't miss this publication from Yale University researchers leveraging JAX models for Kras(LSL-G12D) and Trp53(KO) to generate comprehensive 3D genome atlases of lung and prostate tumors. In parallel with open chromatin analysis and transcriptomics, their work shows promise in predicting cancer states to provide prognosis and potentially optimize cancer therapeutics. Find it here: https://lnkd.in/gGJyQY8X

🔴𝗟𝗶𝘃𝗲 𝗳𝗿𝗼𝗺 𝗔𝗖𝗥𝗧 𝟮𝟬𝟮𝟲 An engaging session by Geeta Upadhyay from Uniformed Services University. 𝗧𝗼𝗽𝗶𝗰: Emerging Biomarkers for Solid Cancer–Immunotherapies A valuable discussion on the discovery of novel biomarkers that can improve patient stratification and enhance the effectiveness of immunotherapies in solid tumors. 𝗠𝗼𝗿𝗲 𝗜𝗻𝗳𝗼: https://lnkd.in/gmKbThMc | Advancements in Cancer Research and Therapeutics More updates coming live from 𝗔𝗖𝗥𝗧 𝟮𝟬𝟮𝟲! #ACRT2026 #Biomarkers #Immunotherapy #CancerResearch #PrecisionMedicine #LiveUpdates

What makes CDK2 an emerging target in cancer therapy? As our understanding of cell-cycle regulation evolves, CDK2 is increasingly recognized as a selective vulnerability in certain tumors. With the help of AI-driven network biology, researchers can now map these molecular dependencies and uncover new therapeutic opportunities. Learn more in our latest article by Sivasankar Putta. Read the full article: https://lnkd.in/gWnAXhNK #ThinkBioAi #CancerBiology #CDK2 #AIinBiotech #DrugDiscovery Pradeep Palazhi | Amit Chaudhuri | Apurva Kalia | Suniti Ponkshe | Anand Aravind | John Rekesh | Michael Evans | Kevin Fleming

This year’s Stanford Cancer Institute Research conference brought together researchers from across Stanford for a full day of discovery, dialogue, and connection. From genomics and artificial intelligence to immunotherapy and new therapeutics, the program reflected the breadth and depth of cancer research at Stanford, and the shared commitment to translating science into impact for patients. Read more: https://brnw.ch/21x15tf #StanfordCancer

🔬 Researchers at Memorial Sloan Kettering Cancer Center analyzed data from more than 5,800 breast cancer patients and found that tumors in people with BRCA2 mutations often develop changes that make CDK4/6 inhibitor therapies less effective over time. In preclinical models, PARP inhibitors performed better, suggesting a possible way to slow or prevent resistance. https://lnkd.in/gwmBSNFt #research